On June 1, 3SBio rose 5.95% at open, trading at HK$19.6/share with trading volume of HK$24.56 million. The rally was driven by continued positive sentiment surrounding the ASCO annual meeting, where the company's core pipeline candidate SSGJ-707, a PD-1/VEGF bispecific antibody, had two clinical studies selected for presentation, with one receiving rapid oral presentation status.

According to published abstracts, SSGJ-707 monotherapy in advanced NSCLC demonstrated a confirmed ORR of 67.6% with median PFS of 12.4 months in a Phase II study. In combination with chemotherapy for first-line endometrial cancer, confirmed ORR reached 85.7% and 80.0% respectively. Additionally, the company recently signed an exclusive licensing agreement with Pfizer for SSGJ-707 worth up to approximately US$6.05 billion, including a US$1.25 billion upfront payment, further validating the asset's global commercial potential. The broader biotech sector also traded stronger, with AKESO up 9.23% and REMEGEN up 2.6%, providing sector-level tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)